Long COVID: major findings, mechanisms and recommendations

Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 21(3), P. 133 - 146

Published: Jan. 13, 2023

Language: Английский

---

The evolution of SARS-CoV-2

Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 21(6), P. 361 - 379

Published: April 5, 2023

Language: Английский

---

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Cell, Journal Year: 2022, Volume and Issue: 186(2), P. 279 - 286.e8

Published: Dec. 14, 2022

The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly due to altered antibody evasion properties deriving from their additional spike mutations. Here, we report that neutralization BQ.1, BQ.1.1, XBB, XBB.1 by sera vaccinees infected persons was markedly impaired, including individuals boosted with a WA1/BA.5 bivalent mRNA vaccine. Titers against were lower 13- 81-fold 66- 155-fold, respectively, far beyond what had been observed date. Monoclonal antibodies capable neutralizing the original variant largely inactive these new subvariants, responsible individual mutations identified. These found have similar ACE2-binding affinities as predecessors. Together, our findings indicate present serious threats current COVID-19 vaccines, render all authorized antibodies, may gained dominance in population because advantage evading antibodies.

Language: Английский

---

Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study

The Lancet, Journal Year: 2022, Volume and Issue: 400(10350), P. 452 - 461

Published: Aug. 1, 2022

Language: Английский

---

Acute and postacute sequelae associated with SARS-CoV-2 reinfection

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(11), P. 2398 - 2405

Published: Nov. 1, 2022

Abstract First infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated increased risk of and postacute death sequelae in various organ systems. Whether reinfection adds to risks incurred after first unclear. Here we used the US Department Veterans Affairs’ national healthcare database build a cohort individuals one SARS-CoV-2 ( n = 443,588), (two or more infections, 40,947) noninfected control 5,334,729). We inverse probability-weighted survival models estimate 6-month burdens death, hospitalization incident sequelae. Compared no reinfection, contributed additional (hazard ratio (HR) 2.17, 95% confidence intervals (CI) 1.93–2.45), (HR 3.32, CI 3.13–3.51) including pulmonary, cardiovascular, hematological, diabetes, gastrointestinal, kidney, mental health, musculoskeletal neurological disorders. The were evident regardless vaccination status. most pronounced phase but persisted at 6 months. controls, cumulative repeat according number infections. Limitations included mostly white males. evidence shows that further increases multiple systems phase. Reducing overall burden disease due will require strategies for prevention.

Language: Английский

---

Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review

EClinicalMedicine, Journal Year: 2022, Volume and Issue: 53, P. 101624 - 101624

Published: Aug. 27, 2022

BackgroundAlthough COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact prevalence long-COVID. The aim this systematic review to investigate association between and long-COVID symptomatology.MethodsMEDLINE, CINAHL, PubMed, EMBASE, Web Science databases, as well medRxiv bioRxiv preprint servers were searched up June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before collected by personal, telephone electronic interviews included. methodological quality was assessed using Newcastle-Ottawa Scale.FindingsFrom 2584 identified, 11 peer-reviewed six 82% (n=14/17) high. Six (n=17,256,654 individuals) investigated vaccines (vaccine-infection-long-COVID design). Overall, associated with reduced risks odds long-COVID, preliminary evidence suggesting that two doses are more effective than one dose. Eleven (n=36,736 survivors) changes in (infection-long-COVID-vaccine Seven articles showed an improvement at least dose post-vaccination, while four reported no change worsening vaccination.InterpretationLow level (grade III, case-controls, cohort studies) suggests could reduce subsequent people existing still controversial, some data showing others did not. These assumptions limited those used studies.FundingThe LONG-COVID-EXP-CM study supported a grant Comunidad de Madrid.

Language: Английский

---

Long-term neurologic outcomes of COVID-19

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(11), P. 2406 - 2415

Published: Sept. 22, 2022

Abstract The neurologic manifestations of acute COVID-19 are well characterized, but a comprehensive evaluation postacute sequelae at 1 year has not been undertaken. Here we use the national healthcare databases US Department Veterans Affairs to build cohort 154,068 individuals with COVID-19, 5,638,795 contemporary controls and 5,859,621 historical controls; inverse probability weighting balance cohorts, estimate risks burdens incident disorders 12 months following SARS-CoV-2 infection. Our results show that in phase there was increased risk an array including ischemic hemorrhagic stroke, cognition memory disorders, peripheral nervous system episodic (for example, migraine seizures), extrapyramidal movement mental health musculoskeletal sensory Guillain–Barré syndrome, encephalitis or encephalopathy. We estimated hazard ratio any sequela 1.42 (95% confidence intervals 1.38, 1.47) burden 70.69 63.54, 78.01) per 1,000 persons months. were elevated even people who did require hospitalization during COVID-19. Limitations include comprising mostly White males. Taken together, our provide evidence long-term had

Language: Английский

---

Prevalence and Correlates of Long COVID Symptoms Among US Adults

JAMA Network Open, Journal Year: 2022, Volume and Issue: 5(10), P. e2238804 - e2238804

Published: Oct. 27, 2022

Importance Persistence of COVID-19 symptoms beyond 2 months, or long COVID, is increasingly recognized as a common sequela acute infection. Objectives To estimate the prevalence and sociodemographic factors associated with COVID to identify whether predominant variant at time infection prior vaccination status are differential risk. Design, Setting, Participants This cross-sectional study comprised 8 waves nonprobability internet survey conducted between February 5, 2021, July 6, 2022, among individuals aged 18 years older, inclusive all 50 states District Columbia. Main Outcomes Measures Long defined reporting continued months after initial month symptoms, self-reported positive results polymerase chain reaction test antigen test. Results The 16 091 respondents test-confirmed illness least had mean age 40.5 (15.2) years; 10 075 (62.6%) were women, 6016 (37.4%) men; 817 (5.1%) Asian, 1826 (11.3%) Black, 1546 (9.6%) Hispanic, 11 425 (71.0%) White. From this cohort, 2359 (14.7%) reported more than illness. Reweighted reflect national distributions, these represented 13.9% those who tested for COVID-19, 1.7% US adults. In logistic regression models, older per decade above 40 (adjusted odds ratio [OR], 1.15; 95% CI, 1.12-1.19) female gender OR, 1.91; 1.73-2.13) greater risk persistence COVID; graduate education vs high school less 0.67; 0.56-0.79) urban rural residence 0.74; 0.64-0.86) likely report COVID. Compared ancestral during periods when Epsilon (OR, 0.81; 0.69-0.95) Omicron 0.77; 0.64-0.92) predominated in was diminished likelihood Completion primary vaccine series 0.72; 0.60-0.86). Conclusions Relevance suggests that prevalent age, while may be by completion

Language: Английский

---

The neurobiology of long COVID

Neuron, Journal Year: 2022, Volume and Issue: 110(21), P. 3484 - 3496

Published: Oct. 7, 2022

Persistent neurological and neuropsychiatric symptoms affect a substantial fraction of people after COVID-19 represent major component the post-acute syndrome, also known as long COVID. Here, we review what is understood about pathobiology impact on CNS discuss possible neurobiological underpinnings cognitive affecting survivors. We propose chief mechanisms that may contribute to this emerging health crisis.

Language: Английский

---

Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study

BMJ, Journal Year: 2023, Volume and Issue: unknown, P. e072529 - e072529

Published: Jan. 11, 2023

Abstract Objectives To determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association age, sex, SARS-CoV-2 variants, vaccination status. Design Retrospective nationwide cohort study. Setting Electronic medical records from an Israeli healthcare organisation. Population 1 913 234 Maccabi Healthcare Services members all ages who did polymerase chain reaction test between March 2020 October 2021. Main outcome measures Risk evidence based list 70 reported outcomes unvaccinated infected matched uninfected people, adjusted age sex stratified by risk breakthrough compared controls. Risks were using hazard ratios differences per 10 000 measured during early (30-180 days) late (180-360 time periods infection. Results Covid-19 was significantly associated increased risks anosmia dysgeusia (hazard ratio 4.59 (95% confidence interval 3.63 5.80), difference 19.6 16.9 22.4) period; 2.96 (2.29 3.82), 11.0 (8.5 13.6) period), cognitive impairment (1.85 (1.58 2.17), 12.8, (9.6 16.1); 1.69 (1.45 1.96), 13.3 (9.4 17.3)), dyspnoea (1.79 (1.68 1.90), 85.7 (76.9 94.5); 1.30 (1.22 1.38), 35.4 (26.3 44.6)), weakness (1.78 (1.69 1.88), 108.5, 98.4 118.6; 1.37), 50.2 (39.4 61.1)), palpitations (1.49 (1.35 1.64), 22.1 (16.8 27.4); 1.16 (1.05 1.27), 8.3 (2.4 14.1)) significant but lower excess streptococcal tonsillitis dizziness. Hair loss, chest pain, cough, myalgia, respiratory disorders only phase. Male female showed minor differences, children had fewer than adults phase covid-19, which mostly resolved period. Findings remained consistent across variants. Vaccinated similar other patients. Conclusions This study suggests that covid-19 are at small number health outcomes, most within diagnosis.

Language: Английский

---